Table 3.

Univariate regression/Crude odds ratios in overall sample.

3a. Probability of outcome given the degree of exposure to CCOP MD or Hospital, among 2003–2005 cases treated at surgical hospital with no/limited medical school affiliation.
Variable/Exposure	Outcome	β	(SE)	OR	95% CI	p value
Proportion of claims from either CCOP MD or hospital	Chemo vs. no chemo	2.384	(0.206)	10.85	[7.25– 16.25]	<.001
Proportion of claims from either CCOP MD or hospital	Oxaliplatin vs. 5-Fu	0.659	(0.168)	1.93	[1.39– 2.68]	<.001
Proportion of claims from either CCOP MD or hospital	Oxaliplatin vs. any other chemo	0.736	(0.165)	2.09	[1.51– 2.88]	<.001

3b. Probability of Oxaliplatin receipt by year of chemotherapy initiation, among 2003–2005 cases treated at surgical hospital with no/limited medical school affiliation.
Variable/Exposure	Outcome	β	(SE)	OR	95% CI	p value
Year of chemo 2003 vs. 2004	Oxaliplatin vs. 5-Fu	−0.983	0.119	0.37	[0.30– 0.47]	<.001
Year of chemo 2005 vs. 2004		0.667	0.109	1.95	[1.57– 2.41]	<.001
Year of chemo 2006 vs. 2004		0.796	0.194	2.22	[1.52– 3.24]	<.001
Year of chemo 2003 vs. 2004	Oxaliplatin vs. any other chemo	−0.904	0.119	0.40	[0.32– 0.51]	<.001
Year of chemo 2005 vs. 2004		0.539	0.102	1.71	[1.41 2.09]	<.001
Year of chemo 2006 vs. 2004		0.815	0.185	2.26	[1.57– 3.25]	<.001